Citations (144)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xuelong Li, Yakun Gao, Yongmei Wang, Ying Wang & Qing Wu. (2023) Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study. Neuropsychiatric Disease and Treatment 19, pages 379-389.
Read now
Read now
Justin Faden, Natasha Kiryankova-Dalseth, Ruby Barghini & Leslie Citrome. (2021) Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. Expert Opinion on Pharmacotherapy 22:5, pages 635-646.
Read now
Read now
Merhawi Bahta, Tzeggai Berhe, Mulugeta Russom, Eyasu H Tesfamariam & Azieb Ogbaghebriel. (2020) Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study. Integrated Pharmacy Research and Practice 9, pages 205-217.
Read now
Read now
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll & André F Carvalho. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management 13, pages 757-777.
Read now
Read now
Sarah E Fitzpatrick, Laura Srivorakiat, Logan K Wink, Ernest V Pedapati & Craig A Erickson. (2016) Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatric Disease and Treatment 12, pages 1525-1538.
Read now
Read now
Britta Galling, Alexandra Roldán, Liz Rietschel, Katsuhiko Hagi, Frozan Walyzada, Wei Zheng, Xiao-Lan Cao, Yu-Tao Xiang, John M. Kane & Christoph U. Correll. (2016) Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Safety 15:5, pages 591-612.
Read now
Read now
Christoffer Polcwiartek, Kristian Kragholm, Ole Schjerning, Claus Graff & Jimmi Nielsen. (2016) Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety 15:5, pages 679-688.
Read now
Read now
K. Joshi, J. Lin, M. Lingohr-Smith & D. J. Fu. (2015) Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics 18:8, pages 629-636.
Read now
Read now
Articles from other publishers (136)
Juliette Lagreula, Vincent Dagenais‐Beaulé, Philippe de Timary, Laure Elens & Olivia Dalleur. (2023) Prescribing and deprescribing trends in schizophrenia: An overview of inpatients in Belgium and in the Canadian province of Québec. Basic & Clinical Pharmacology & Toxicology 133:6, pages 691-702.
Crossref
Crossref
Carina Lundby, Marianne Nielsen, Trine Simonsen, Stine Galsgaard, Maija Bruun Haastrup, Lene Vestergaard Ravn‐Nielsen & Anton Pottegård. (2023) Attitudes towards deprescribing in geriatric psychiatry: A survey among older psychiatric outpatients. Basic & Clinical Pharmacology & Toxicology.
Crossref
Crossref
Taro Kishi, Yasuhiro Iwama, Yuji Sasagawa, Shuichi Hiraoka, Aya Kamei & Nakao Iwata. (2023) Asenapine add‐on treatment for schizophrenia adults who received antipsychotics: A 52‐week, open‐label study. Psychiatry and Clinical Neurosciences 77:6, pages 365-366.
Crossref
Crossref
Yoshitaka Kyou, Satoru Oishi, Takeya Takizawa, Yuki Yoshimura, Itsuki Hashimoto, Ryutaro Suzuki, Reina Demizu, Tsuyoshi Ono, Yuka Noguchi, Tomohiko Kimura, Ken Inada & Hitoshi Miyaoka. (2023)
Influence of Psychotropic
Pro Re Nata
Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
. Clinical Psychopharmacology and Neuroscience 21:2, pages 332-339.
Crossref
Crossref
Jan P A M Bogers, George Hambarian, Niels Walburgh Schmidt, Jentien M Vermeulen & Lieuwe de Haan. (2023) Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin 49:1, pages 11-23.
Crossref
Crossref
Chin-Wei Kuo, Szu-Chun Yang, Yu-Fen Shih, Xin-Min Liao & Sheng-Hsiang Lin. (2022) Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Marta Balog, Allison C Anderson, Marija Heffer, Zeljka Korade & Karoly Mirnics. (2022) Effects of Psychotropic Medication on Somatic Sterol Biosynthesis of Adult Mice. Biomolecules 12:10, pages 1535.
Crossref
Crossref
Giammarco Cascino, Rossella Ceres, Alessio Maria Monteleone, Paola Bucci, Giulia Maria Giordano, Silvana Galderisi & Palmiero Monteleone. (2022) Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study. Journal of Clinical Medicine 11:19, pages 5965.
Crossref
Crossref
Sanghoon Oh, Sun-ju Byeon & Soo Jie Chung. (2022) Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Journal of Psychopharmacology 36:9, pages 1041-1050.
Crossref
Crossref
Yi-Hsuan Lin, Chi-Shin Wu, Chen-Chung Liu, Po-Hsiu Kuo, Hung-Yu Chan & Wei J Chen. (2022) Comparative Effectiveness of Antipsychotics in Preventing Readmission for First-Admission Schizophrenia Patients in National Cohorts From 2001 to 2017 in Taiwan. Schizophrenia Bulletin 48:4, pages 785-794.
Crossref
Crossref
Cuifang Zhu, Ruofan Li, Mingliang Ju, Xudong Xiao, Ti-Fei Yuan, Zhixing Jin & Jing Zhao. (2022) Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial. Frontiers in Molecular Neuroscience 15.
Crossref
Crossref
Laurie K. McLay, Nicholas J. Bowden, Matthew J.F. Eggleston, Hiran Thabrew, Rhiannon Braund & Philip J. Schluter. (2022) Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study. Research in Autism Spectrum Disorders 93, pages 101948.
Crossref
Crossref
Justin C. Yang, Johan H. Thygesen, Nomi Werbeloff, Joseph F. Hayes & David P. J. Osborn. (2022) Antipsychotic polypharmacy and adverse drug reactions among adults in a London mental health service, 2008–2018. Psychological Medicine, pages 1-8.
Crossref
Crossref
Pedro Cabral Barata. (2021) “Polypharmacy in neuroleptics side‐effects comparison: a bias not to be overlooked”. Early Intervention in Psychiatry 16:3, pages 323-324.
Crossref
Crossref
My Linh Nguyen, Bruce Sunderland, Stephen Lim, Laetitia Hattingh & Leanne Chalmers. (2022) A qualitative exploration of factors contributing to non-guideline adherent antipsychotic polypharmacy. Research in Social and Administrative Pharmacy 18:3, pages 2457-2467.
Crossref
Crossref
Tae MAESHIMA, Machiko WATANABE & Fumio ITAGAKI. (2022) Risk of Unfavorable Outcomes of Thromboembolism with Antipsychotic Drug Use: Analysis Using the Japanese Adverse Drug Event Report Database. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 53:1, pages 3-10.
Crossref
Crossref
Juliette Lagreula, Philippe de Timary, Laure Elens & Olivia Dalleur. (2022) Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation. Therapeutic Advances in Psychopharmacology 12, pages 204512532211125.
Crossref
Crossref
Jie Li & Shen Li. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
855
867
.
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Stephan Hjorth. (2021) The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. Frontiers in Psychiatry 12.
Crossref
Crossref
Olena Khaustova & Dmytro Assonov. (2021) The use of antipsychotics in targeted therapy of schizophrenia — prospects and challenges (for example, amisulpride).. Ukrains'kyi Visnyk Psykhonevrolohii:Volume 29, issue 2 (107), pages 83-89.
Crossref
Crossref
Nobutaka Ayani, Takeshi Morimoto, Mio Sakuma, Toshiaki Kikuchi, Koichiro Watanabe & Jin Narumoto. (2021) Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients. Journal of Clinical Psychopharmacology 41:4, pages 397-402.
Crossref
Crossref
Markku Lähteenvuo & Jari Tiihonen. (2021) Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs 81:11, pages 1273-1284.
Crossref
Crossref
Soo Min Jeon, Susan Park, Soonhak Kwon & Jin-Won Kwon. (2021) Association Between Antipsychotic Treatment and Neurological Adverse Events in Pediatric Patients: A Population-Based Cohort Study in Korea. Frontiers in Psychiatry 12.
Crossref
Crossref
Frank M. C. Besag, Michael J. Vasey & Iffah Salim. (2021) Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review. CNS Drugs 35:5, pages 507-526.
Crossref
Crossref
Sérgio Martinho, Ana Poças, Mário Simões & Cláudio Laureano. (2020) Antipsychotic Polypharmacy and High-Dose Antipsychotics in Involuntary Patients: a Seven-Year Audit of Discharge Prescriptions in an Acute Care Unit. Psychiatric Quarterly 92:1, pages 1-14.
Crossref
Crossref
Ivana Clark, Phoebe Wallman, Victoria Cornelius & David Taylor. (2021) Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: A 2-year naturalistic follow-up study. European Psychiatry 64:1.
Crossref
Crossref
Christian Fyhn Reuss, Jørgen Bo Hasselstrøm, Kristian Linnet, Dorte Jensen Christoffersen, Peter Mygind Leth, Lene Warner Thorup Boel & Jytte Banner. (2020) Increased risk of fatal intoxication and polypharmacy among psychiatric patients at death. Journal of Forensic Sciences 66:1, pages 255-264.
Crossref
Crossref
Eric C. Alcera, Michelle Jaehning & Ramon Solhkhah. 2021. Emerging Programs for Autism Spectrum Disorder. Emerging Programs for Autism Spectrum Disorder
303
335
.
Melissa Allen, Yasmin Gharbaoui, Chester Wu, Noha Abdel-Gawad & Mollie Gordon. 2021. Sleep Disorders in Selected Psychiatric Settings. Sleep Disorders in Selected Psychiatric Settings
111
122
.
Freja Karuna Hemmingsen Sørup, Søren Brunak & Robert Eriksson. (2020) Association between antipsychotic drug dose and length of clinical notes: a proxy of disease severity?. BMC Medical Research Methodology 20:1.
Crossref
Crossref
Torleif Ruud, Karin Drivenes, Robert E. Drake, Vegard Øksendal Haaland, Matthew Landers, Bjørn Stensrud, Kristin S. Heiervang, Lars Tanum & Gary R. Bond. (2020) The Antipsychotic Medication Management Fidelity Scale: Psychometric properties. Administration and Policy in Mental Health and Mental Health Services Research 47:6, pages 911-919.
Crossref
Crossref
Adriana FosterJordanne King. (2020) Antipsychotic Polypharmacy. FOCUS 18:4, pages 375-385.
Crossref
Crossref
. (2020) Progress in Schizophrenia Research and Treatment. FOCUS 18:4, pages 440-442.
Crossref
Crossref
Sharea Ijaz, Blanca Bolea, Simon Davies, Jelena Savović, Alison Richards, Sarah Sullivan & Paul Moran. (2020) Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia: A Review of Systematic Reviews. FOCUS 18:4, pages 482-492.
Crossref
Crossref
Norio Yasui‐Furukori & Kazutaka Shimoda. (2020) Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia. Neuropsychopharmacology Reports 40:3, pages 208-210.
Crossref
Crossref
Aybeniz Civan Kahve, Hasan Kaya, Atike Gül Çakıl, Esra Ünverdi Bıçakçı, Pelin Göksel, Erol Göka & Ömer Böke. (2020) Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?. Asian Journal of Psychiatry 52, pages 102063.
Crossref
Crossref
Martina Rojnic Kuzman, Porin Makaric, Dina Bosnjak Kuharic, Ivana Kekin, Zoran Madzarac, Ana Koricancic Makar, Zarko Bajic, Drazenka Ostojic, Ante Silic & Maja Zivkovic. (2020) General Functioning in Patients With First-Episode Psychosis After the First 18 Months of Treatment. Journal of Clinical Psychopharmacology 40:4, pages 366-372.
Crossref
Crossref
S. Mas, P. Gassó, N. Rodríguez, B. Cabrera, G. Mezquida, A. Lobo, A. González‐Pinto, M. Parellada, I. Corripio, E. Vieta, J. Castro‐Fornieles, J. Bobes, J. Usall, J. Saiz‐Ruiz, F. Contreras, E. Parellada, M. Bernardo, Amalia Lafuente, Miquel Bioque, Covadonga M. Diaz‐Caneja, Javier González‐Peñas, Anna Alonso Solis, Mireia Rebella, Itxaso González‐Ortega, Ariadna Besga, Julio SanJuan, Juan Nacher, Laura Morro, Clara Montserrat, Esther Jimenez, Susana Gomes Da Costa, Immaculada Baeza, Elena de la Serna, S Rivas, C Diaz, Pilar A Saiz, Leticia Garcia‐Álvarez, Miguel Gutierrez Fraile, Arantzazu Zabala Rabadán, Iosune Torio, Roberto Rodríguez‐Jimenez, Anna Butjosa, Marta Pardo, Salvador Sarró, Edith Pomarol‐Clotet, Angela Ibañez Cuadrado & Manuel J Cuesta. (2019) Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first‐episode psychosis cohort. Acta Psychiatrica Scandinavica 141:6, pages 541-552.
Crossref
Crossref
Alexis E. Horace, Negar Golchin, Elia M. Pestana Knight, Neal V. Dawson, Xuan Ma, James A. Feinstein, Hannah K. Johnson, Lawrence Kleinman & Paul M. Bakaki. (2019) A Scoping Review of Medications Studied in Pediatric Polypharmacy Research. Pediatric Drugs 22:1, pages 85-94.
Crossref
Crossref
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U. Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock & Joachim Cordes. (2019) A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 83-94.
Crossref
Crossref
Thomas R. E. Barnes, James H. MacCabe, John M. Kane, Oriana Delgado & Carol Paton. (2020) The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. Therapeutic Advances in Psychopharmacology 10, pages 204512532093790.
Crossref
Crossref
Jan P A M Bogers, George Hambarian, Maykel Michiels, Jentien Vermeulen & Lieuwe de Haan. (2020) Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin Open 1:1.
Crossref
Crossref
Jie Li & Shen Li. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
13
.
Su-Zhen Zhang, Yong-Gang Mu, Qi Liu, Ying Shi, Li-Hua Guo, Ling-Zhi Li, Fu-De Yang, Yong Wang, Tao Li, Qi-Yi Mei, Hong-Bo He, Zhi-Yu Chen, Zhong-Hua Su, Tie-Bang Liu, Shi-Ping Xie, Qing-Rong Tan, Jin-Bei Zhang, Cong-Pei Zhang, Hong Sang, Wei-Feng Mi & Hong-Yan Zhang. (2019) Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study. BMC Psychiatry 19:1.
Crossref
Crossref
Min Dong, Liang-Nan Zeng, Qinge Zhang, Shu-Yu Yang, Lian-Yu Chen, Kang Sim, Yan-Ling He, Helen Fung-Kum Chiu, Norman Sartorius, Chay-Hoon Tan, Mian-Yoon Chong, Naotaka Shinfuku, Shih-Ku Lin, Chee H. Ng, Gabor S. Ungvari & Yu-Tao Xiang. (2019) Antipsychotic Polypharmacy in Older Adult Asian Patients With Schizophrenia: Research on Asian Psychotropic Prescription Pattern. Journal of Geriatric Psychiatry and Neurology 32:6, pages 304-311.
Crossref
Crossref
Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Zhan-Ming Shi, Mei-Ling Hu, Yu-Ping Ning & Yu-Tao Xiang. (2019) Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. General Psychiatry 32:5, pages e100091.
Crossref
Crossref
Min Dong, Liang-Nan Zeng, Qinge Zhang, Shu-Yu Yang, Lian-Yu Chen, Eunice Najoan, Roy Abraham Kallivayalil, Kittisak Viboonma, Ruzita Jamaluddin, Afzal Javed, Duong Thi Quynh Hoa, Hitoshi Iida, Kang Sim, Thiha Swe, Yan-Ling He, Yongchon Park, Helal Uddin Ahmed, Angelo De Alwis, Helen F.K. Chiu, Norman Sartorius, Chay-Hoon Tan, Mian-Yoon Chong, Naotaka Shinfuku, Shih-Ku Lin, Ajit Avasthi, Sandeep Grover, Chee H. Ng, Gabor S. Ungvari & Yu-Tao Xiang. (2019) Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. Asian Journal of Psychiatry 45, pages 74-80.
Crossref
Crossref
Negar Golchin, Hannah Johnson, Paul M. Bakaki, Neal Dawson, Elia M. Pestana Knight, Sharon B. Meropol, Rujia Liu, James A. Feinstein, Shari D. Bolen, Lawrence C. Kleinman & Alexis Horace. (2019) Outcome measures in pediatric polypharmacy research: a scoping review. Drugs & Therapy Perspectives 35:9, pages 447-458.
Crossref
Crossref
Shreedhar Paudel, Rabin Dahal, Joseph Mathias, Sushrusha Arjyal & Liliana Markovic. (2019) Evaluation of Risk Factors for Antipsychotic Polypharmacy in Inpatient Psychiatry Units of a Community Hospital: A Retrospective Analysis. Community Mental Health Journal 55:5, pages 750-754.
Crossref
Crossref
Maximilian Huhn, Myrto Samara & Stefan Leucht. (2019) Pharmakotherapie der therapieresistenten Schizophrenie. PSYCH up2date 13:03, pages 223-240.
Crossref
Crossref
Donald C. Goff. (2019) Can Adjunctive Pharmacotherapy Reduce Hospitalization in Schizophrenia?. JAMA Psychiatry 76:5, pages 468.
Crossref
Crossref
Jennifer N. Alastanos, Chris Paxos & Jessica Emshoff. (2019) Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting. Mental Health Clinician 9:1, pages 18-23.
Crossref
Crossref
O. O. Kirilochev & A. R. Umerova. (2019) Safety of psychopharmacotherapy: a clinical and pharmacological approach. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 127.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Jonathan Brett, Helga Zoega, Nicholas A. Buckley, Benjamin J. Daniels, Adam G. Elshaug & Sallie-Anne Pearson. (2018) Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia. BMC Health Services Research 18:1.
Crossref
Crossref
Sharea Ijaz, Blanca Bolea, Simon Davies, Jelena Savović, Alison Richards, Sarah Sullivan & Paul Moran. (2018) Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 18:1.
Crossref
Crossref
Paul M. Bakaki, Alexis Horace, Neal Dawson, Almut Winterstein, Jennifer Waldron, Jennifer Staley, Elia M. Pestana Knight, Sharon B. Meropol, Rujia Liu, Hannah Johnson, Negar Golchin, James A. Feinstein, Shari D. Bolen & Lawrence C. Kleinman. (2018) Defining pediatric polypharmacy: A scoping review. PLOS ONE 13:11, pages e0208047.
Crossref
Crossref
Martina Rojnic Kuzman, Dina Bosnjak Kuharic, Ivana Kekin, Porin Makaric, Zoran Madzarac, Ana Koricancic Makar, Suzan Kudlek Mikulic, Zarko Bajic, Petra Bistrovic, Dora Bonacin & Zeljka Vogrinc. (2018) Effects of Long-Term Multimodal Psychosocial Treatment on Antipsychotic-Induced Metabolic Changes in Patients With First Episode Psychosis. Frontiers in Psychiatry 9.
Crossref
Crossref
Wei Zheng, Dong-Bin Cai, Hai-Yan Li, Yu-Jie Wu, Chee H Ng, Gabor S Ungvari, Shan-Shan Xie, Zhan-Ming Shi, Xiao-Min Zhu, Yu-Ping Ning & Yu-Tao Xiang. (2018) Adjunctive Peony-Glycyrrhiza decoction for antipsychotic-induced hyperprolactinaemia: a meta-analysis of randomised controlled trials. General Psychiatry 31:1, pages e100003.
Crossref
Crossref
Jan P.A.M. Bogers, Peter F.J. Schulte, Theo G. Broekman, Peter Moleman & Lieuwe de Haan. (2018) Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European Neuropsychopharmacology 28:9, pages 1024-1034.
Crossref
Crossref
P. Riedel, M. N. Smolka & M. Bauer. (2018) Schizophrenie und bipolare StörungSchizophrenia and bipolar disorder. Der Nervenarzt 89:7, pages 784-795.
Crossref
Crossref
Thea Bjune, Bjarke Risgaard, Line Kruckow, Charlotte Glinge, Ole Ingemann-Hansen, Peter Mygind Leth, Kristian Linnet, Jytte Banner, Bo Gregers Winkel & Jacob Tfelt-Hansen. (2018) Post-mortem toxicology in young sudden cardiac death victims: a nationwide cohort study. EP Europace 20:4, pages 614-621.
Crossref
Crossref
Lisa M. Kalisch Ellett, Nicole L. Pratt, Mhairi Kerr & Elizabeth E. Roughead. (2017) Antipsychotic polypharmacy in older Australians. International Psychogeriatrics 30:4, pages 539-546.
Crossref
Crossref
Trude Seselie Jahr Iversen, Nils Eiel Steen, Ingrid Dieset, Sigrun Hope, Ragni Mørch, Erlend Strand Gardsjord, Kjetil Nordbø Jørgensen, Ingrid Melle, Ole A. Andreassen, Espen Molden & Erik G. Jönsson. (2018) Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 82, pages 263-271.
Crossref
Crossref
Jonathan Brett, Adam G. Elshaug, R. Sacha Bhatia, Kelsey Chalmers, Tim Badgery-Parker & Sallie-Anne Pearson. (2017) A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implementation Science 12:1.
Crossref
Crossref
Drigissa Ilies, Anne-Sophie Huet, Eric Lacourse, Geneviève Roy, Emmanuel Stip & Leila Ben Amor. (2017) Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study. The Canadian Journal of Psychiatry 62:12, pages 827-836.
Crossref
Crossref
Yu-Tao Xiang, Takahiro A. Kato, Taishiro Kishimoto, Gabor S. Ungvari, Helen F.K. Chiu, Tian-Mei Si, Shu-Yu Yang, Senta Fujii, Chee H. Ng & Naotaka Shinfuku. (2017) Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009). Asia-Pacific Psychiatry 9:4, pages e12277.
Crossref
Crossref
Jonathan Brett, Benjamin Daniels, Emily A. Karanges, Nicholas A. Buckley, Carl Schneider, Atheer Nassir, Andrew J. McLachlan & Sallie-Anne Pearson. (2017) Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. British Journal of Clinical Pharmacology 83:11, pages 2581-2588.
Crossref
Crossref
Sang Jeon & Yong-Ku Kim. (2017) Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. International Journal of Molecular Sciences 18:10, pages 2174.
Crossref
Crossref
Adriana FosterPeter BuckleyJohn LaurielloStephen LooneyNina Schooler. (2017) Combination Antipsychotic Therapies. Journal of Clinical Psychopharmacology 37:5, pages 595-599.
Crossref
Crossref
S.G. Pristed, C.U. Correll & J. Nielsen. (2017) Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. Psychiatry Research 255, pages 198-203.
Crossref
Crossref
Qian Li, Yun-Ai Su, Yu-Tao Xiang, Liang Shu, Xin Yu, Gabor S. Ungvari, Stephen J. Seiner, Helen F.K. Chiu, Yu-Ping Ning, Gao-Hua Wang, Ke-Rang Zhang, Tao Li, Li-Zhong Sun, Jian-Guo Shi, Xian-Sheng Chen, Qi-Yi Mei, Ke-Qing Li & Tian-Mei Si. (2017) Electroconvulsive Therapy in Schizophrenia in China. The Journal of ECT 33:2, pages 138-142.
Crossref
Crossref
D. J. Siskind, M. Harris, A. Phillipou, V. A. Morgan, A. Waterreus, C. Galletly, V. J. Carr, C. Harvey & D. Castle. (2016) Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiology and Psychiatric Sciences 26:3, pages 325-337.
Crossref
Crossref
Masakazu Hatano, Hiroyuki Kamei, Azusa Kato, Ippei Takeuchi, Manako Hanya, Junji Uno, Shigeki Yamada, Kiyoshi Fujita & Nakao Iwata. (2017) Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience 15:2, pages 132-137.
Crossref
Crossref
Logan K. WinkErnest V. PedapatiPaul S. HornChristopher J. McDougleCraig A. Erickson. (2017) Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology 27:1, pages 91-94.
Crossref
Crossref
B.O. James, J.O. Omoaregba, S.O. Raji, O.E. Imishue, K.M. Okonoda, Y.I. Nyamali, P.A. Famuyiwa & C.U. Correll. (2017) Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. Psychiatry Research 248, pages 134-139.
Crossref
Crossref
Britta Galling, Alexandra Roldán, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao‐Lan Cao, Yu‐Tao Xiang, Mathias Zink, John M. Kane, Jimmi Nielsen, Stefan Leucht & Christoph U. Correll. (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis. World Psychiatry 16:1, pages 77-89.
Crossref
Crossref
K. Jobski, J. Höfer, F. Hoffmann & C. Bachmann. (2017) Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatrica Scandinavica 135:1, pages 8-28.
Crossref
Crossref
. 2017. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
111
.
Christopher BellonciMegan BakerJonathan C. HuefnerRobert J. Hilt. (2016) Deprescribing and Its Application to Child Psychiatry. Child and Adolescent Psychopharmacology News 21:6, pages 1-9.
Crossref
Crossref
Madison L. Gates, Thad Wilkins, Elizabeth Ferguson, Veronica Walker, Robert K. Bradford & Wonsuk Yoo. (2016) Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications. Health & Justice 4:1.
Crossref
Crossref
Daniel Bressington, Jolene Mui, Mei Ling Tse, Richard Gray, Eric F. C. Cheung & Wai Tong Chien. (2016) Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study. BMC Psychiatry 16:1.
Crossref
Crossref
Qijing Bo, Fang Dong, Xianbin Li, Zhimin Wang, Xin Ma & Chuanyue Wang. (2016) Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. BMC Psychiatry 16:1.
Crossref
Crossref
Feng-Rong An, Rui Yang, Zhi-Min Wang, Gabor S. Ungvari, Chee H. Ng, Helen F.K. Chiu, Ping-Ping Wu, Xin Jin, Lu Li, Grace K.I. Lok & Yu-Tao Xiang. (2016) Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients. Comprehensive Psychiatry 71, pages 71-76.
Crossref
Crossref
Kruti JoshiJay LinMelissa Lingohr-SmithDong-Jing FuErik Muser. (2016) Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. Journal of Clinical Psychopharmacology 36:5, pages 429-435.
Crossref
Crossref
GLORIMAR ORTIZ, VERA HOLLEN & LUCILLE SCHACHT. (2016) Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals. Journal of Psychiatric Practice 22:4, pages 283-297.
Crossref
Crossref
Katherine W. Scangos, Michael Caton & William J. Newman. (2016) Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 36:3, pages 283-285.
Crossref
Crossref
John C. Hammond, Adrienne C. Lahti & Nina V. Kraguljac. (2016) Rapid Clozapine Titration in an Acutely Agitated Patient With Schizoaffective Disorder. Journal of Clinical Psychopharmacology 36:3, pages 276-277.
Crossref
Crossref
Cherrie Galletly, David Castle, Frances Dark, Verity Humberstone, Assen Jablensky, Eóin Killackey, Jayashri Kulkarni, Patrick McGorry, Olav Nielssen & Nga Tran. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry 50:5, pages 410-472.
Crossref
Crossref
Niklas Schmedt, Kathrin Jobski, Bianca Kollhorst, Jutta Krappweis, Eckart Rüther, Tania Schink & Edeltraut Garbe. (2016) Treatment patterns and characteristics of older antipsychotic users in Germany. International Clinical Psychopharmacology 31:3, pages 159-169.
Crossref
Crossref
Y.-T. Xiang, G. S. Ungvari, C. U. Correll, H. F. K. Chiu & N. Shinfuku. (2015) Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiology and Psychiatric Sciences 25:1, pages 9-17.
Crossref
Crossref
Pawel Mierzejewski, Marcin Kolaczkowski, Monika Marcinkowska, Anna Wesolowska, Jerzy Samochowiec, Maciej Pawlowski & Przemyslaw Bienkowski. (2016) Antipsychotic-like effects of zolpidem in Wistar rats. European Journal of Pharmacology 773, pages 51-58.
Crossref
Crossref
Yuki Shigetsura, Manami Koike, Yuichiro Kayano, Sachio Fukatsu, Ryoko Ishizuka, Genichi Sugihara, Satoshi Imai, Ikuko Yano, Takayuki Nakagawa, Toshiya Murai & Kazuo Matsubara. (2016) Impacts of Pharmacist Intervention on Psychotropic Polypharmacy and Fall Accidents. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 42:3, pages 174-184.
Crossref
Crossref
Hirokazu Ito, Misao Miyagawa, Kazuhiro Ozawa, Tetsuya Tanioka, Yuko Yasuhara, Mutsuko Kataoka, Beth King, Masahito Tomotake, Yumi Kuwamura & Rozzano C. Locsin. (2016) Prioritizing Patient Assessment Data (PAD) Using the Japanese Psychiatric Nursing Assessment Classification System (PsyNACS)©. Open Journal of Psychiatry 06:03, pages 218-227.
Crossref
Crossref
Hirokazu Ito, Misao Miyagawa, Kazuhiro Ozawa, Tetsuya Tanioka, Yuko Yasuhara, Mutsuko Kataoka, Beth King, Masahito Tomotake & Rozzano C. Locsin. (2016) The Development of the Japanese Psychiatric Nursing Assessment Classification System (PsyNACS<sup>©</sup>). Open Journal of Psychiatry 06:01, pages 20-33.
Crossref
Crossref
Stefan Leucht. 2016. Praxishandbuch Schizophrenie. Praxishandbuch Schizophrenie
157
176
.
Dan Cohen. 2016. Life-Threatening Effects of Antipsychotic Drugs. Life-Threatening Effects of Antipsychotic Drugs
311
332
.
Jack E. James. 2016. The Health of Populations. The Health of Populations
429
464
.
Benno Schimmelmann, Claudia Mehler-Wex & Christoph Wewetzer. 2016. Neuro-/Psychopharmaka im Kindes- und Jugendalter. Neuro-/Psychopharmaka im Kindes- und Jugendalter
551
559
.
Qian Li, Yu-Tao Xiang, Yun-Ai Su, Liang Shu, Xin Yu, Christoph U. Correll, Gabor S. Ungvari, Helen F.K. Chiu, Cui Ma, Gao-Hua Wang, Pei-Shen Bai, Tao Li, Li-Zhong Sun, Jian-Guo Shi, Xian-Sheng Chen, Qi-Yi Mei, Ke-Qing Li, Tian-Mei Si & John M. Kane. (2015) Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012). Schizophrenia Research 168:1-2, pages 523-529.
Crossref
Crossref
Benjamin Sneider, Sofie Gry Pristed, Christoph U. Correll & Jimmi Nielsen. (2015) Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. European Neuropsychopharmacology 25:10, pages 1669-1676.
Crossref
Crossref
P. Manu, L. Dima, M. Shulman, D. Vancampfort, M. De Hert & C. U. Correll. (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica 132:2, pages 97-108.
Crossref
Crossref
Robert J. Constantine, Ross Andel, Marie McPherson & Rajiv Tandon. (2015) The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial. Schizophrenia Research 166:1-3, pages 194-200.
Crossref
Crossref
Jing-Xu Chen, Yun-Ai Su, Qing-Tao Bian, Li-He Wei, Rong-Zhen Zhang, Yan-Hong Liu, Christoph Correll, Jair C. Soares, Fu-De Yang, Shao-Li Wang & Xiang-Yang Zhang. (2015) Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose–response study. Psychoneuroendocrinology 58, pages 130-140.
Crossref
Crossref
Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington & Hiroyuki Uchida. (2015) Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. The Canadian Journal of Psychiatry 60:5, pages 215-222.
Crossref
Crossref
Alexander Panickacheril John & Milan Dragovic. (2015) Antipsychotic Polypharmacy Is Not Associated With Reduced Dose of Individual Antipsychotics in Schizophrenia. Journal of Clinical Psychopharmacology 35:2, pages 193-195.
Crossref
Crossref
W. Gaebel, I. Großimlinghaus, R. Heun, B. Janssen, B. Johnson, T. Kurimay, P. Montellano, M. Muijen, P. Munk-Jorgensen, W. Rössler, M. Ruggeri, G. Thornicroft & J. Zielasek. (2020) European Psychiatric Association (EPA) guidance on quality assurance in mental healthcare. European Psychiatry 30:3, pages 360-387.
Crossref
Crossref
Qian Li, Yu-Tao Xiang, Yun-Ai Su, Liang Shu, Xin Yu, Helen FK Chiu, Christoph U Correll, Gabor S Ungvari, Kelly YC Lai, Cui Ma, Gao-Hua Wang, Pei-Shen Bai, Tao Li, Li-Zhong Sun, Jian-Guo Shi, Xian-Sheng Chen, Qi-Yi Mei, Ke-Qing Li & Tian-Mei Si. (2014) Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. Australian & New Zealand Journal of Psychiatry 49:2, pages 129-136.
Crossref
Crossref
. 2015. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
e1
e96
.
Susanne Englisch & Mathias Zink. 2015. Obsessive-Compulsive Symptoms in Schizophrenia. Obsessive-Compulsive Symptoms in Schizophrenia
179
202
.
Maxine D Fisher, Kathleen Reilly, Keith Isenberg & Kathleen F Villa. (2014) Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. BMC Psychiatry 14:1.
Crossref
Crossref
Zhi-Min Wang, Yu-Tao Xiang, Feng-Rong An, Christoph U. Correll, Gabor S. Ungvari, Chuan-Yue Wang, Kelly Y. C. Lai, Qi-Jing Bo, Yan Li, Bao-Liang Zhong & Helen F. K. Chiu. (2014) Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China. Perspectives in Psychiatric Care 50:4, pages 257-263.
Crossref
Crossref
Virginie Dauphinot, Rémi Faure, Sélim Omrani, Sylvain Goutelle, Laurent Bourguignon, Pierre Krolak-Salmon & Christelle Mouchoux. (2014) Exposure to Anticholinergic and Sedative Drugs, Risk of Falls, and Mortality. Journal of Clinical Psychopharmacology 34:5, pages 565-570.
Crossref
Crossref
Othman Mohammad & David N. Osser. (2014) The Psychopharmacology Algorithm Project at the Harvard South Shore Program. Harvard Review of Psychiatry 22:5, pages 274-294.
Crossref
Crossref
Shannon N. Saldaña, Brooks R. Keeshin, Anna M. Wehry, Thomas J. Blom, Michael T. Sorter, Melissa P. DelBello & Jeffrey R. Strawn. (2014) Antipsychotic Polypharmacy in Children and Adolescents at Discharge from Psychiatric Hospitalization. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:8, pages 836-844.
Crossref
Crossref
S. Gee, F. Vergunst, O. Howes & D. Taylor. (2013) Practitioner attitudes to clozapine initiation. Acta Psychiatrica Scandinavica 130:1, pages 16-24.
Crossref
Crossref
Nitin Toteja, Juan A. Gallego, Ema Saito, Tobias Gerhard, Almut Winterstein, Mark Olfson & Christoph U. Correll. (2013) Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. The International Journal of Neuropsychopharmacology 17:07, pages 1095-1105.
Crossref
Crossref
Anthony P. Polednak. (2014) Trend in rates for deaths with mention of schizophrenia on death certificates of US residents, 1999–2010. Social Psychiatry and Psychiatric Epidemiology 49:7, pages 1083-1091.
Crossref
Crossref
Natasa Gisev, J. Simon Bell & Timothy F. Chen. (2014) Factors Associated With Antipsychotic Polypharmacy and High-Dose Antipsychotics Among Individuals Receiving Compulsory Treatment in the Community. Journal of Clinical Psychopharmacology 34:3, pages 307-312.
Crossref
Crossref
Markus Dold & Stefan Leucht. (2014) Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evidence Based Mental Health 17:2, pages 33-37.
Crossref
Crossref
Felice Iasevoli, Elisabetta F. Buonaguro, Massimo Marconi, Emanuela Di Giovambattista, Maria Paola Rapagnani, Domenico De Berardis, Giovanni Martinotti, Monica Mazza, Raffaele Balletta, Nicola Serroni, Massimo Di Giannantonio, Andrea de Bartolomeis & Alessandro Valchera. (2014) Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study. ISRN Pharmacology 2014, pages 1-9.
Crossref
Crossref
Jinyoung ChoiShi Hyun KangJong-Il LeeYujeong HaHai Joo YoonEunkyung ParkDong Yeon Park. (2014) Clinical Correlates and Description Profiles of Antipsychotic Polypharmacy for Patients with Schizophrenia. Journal of Korean Neuropsychiatric Association 53:6, pages 370.
Crossref
Crossref
Daeyoung Roh, Jhin-Goo Chang, Chan-Hyung Kim, Hyun-Sang Cho, Suk Kyoon An & Young-Chul Jung. (2013) Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Australian & New Zealand Journal of Psychiatry 48:1, pages 52-60.
Crossref
Crossref
. 2014. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
1
91
.
Benno G. Schimmelmann, Claudia Mehler-Wex & Christoph Wewetzer. 2014. Psychiatric Drugs in Children and Adolescents. Psychiatric Drugs in Children and Adolescents
499
506
.
Licia Maiocchi & Elsa Bernardi. (2013) Optimisation of prescription in patients with long-term treatment-resistant schizophrenia. Australasian Psychiatry 21:5, pages 446-448.
Crossref
Crossref
Taishiro Kishimoto, Koichiro Watanabe, Hiroyuki Uchida, Masaru Mimura, John M. Kane & Christoph U. Correll. (2013) Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. Psychiatry Research 209:3, pages 406-411.
Crossref
Crossref
Steven M. Burghart. (2013) Antipsychotic polypharmacy and Joint Commission quality measures: Implications to the psychiatric pharmacist. Mental Health Clinician 3:1, pages 10-12.
Crossref
Crossref
Alessandro Serretti, Alberto Chiesa, Raffaella Calati, Chiara Fabbri, Othman Sentissi, Diana De Ronchi, Julien Mendlewicz & Daniel Souery. (2013) Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology 27:7, pages 616-628.
Crossref
Crossref
Elena Rubio-Abadal & Judith Usall. (2013) Hiperprolactinemia y tratamiento antipsicótico. Manifestaciones clínicas y manejo. Psiquiatría Biológica 20:3, pages 27-34.
Crossref
Crossref
Jacob Ballon & T. Scott Stroup. (2013) Polypharmacy for schizophrenia. Current Opinion in Psychiatry 26:2, pages 208-213.
Crossref
Crossref
Ursula Werneke, David Taylor & Thomas A. B. Sanders. (2013) Behavioral Interventions for Antipsychotic Induced Appetite Changes. Current Psychiatry Reports 15:3.
Crossref
Crossref
Heidi N. Boyda, Ric M. Procyshyn, Catherine C. Y. Pang, Erin Hawkes, Daniel Wong, Chen Helen Jin, William G. Honer & Alasdair M. Barr. (2013) Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine. PLoS ONE 8:1, pages e53459.
Crossref
Crossref
Christoph U. Correll & Juan A. Gallego. (2012) Antipsychotic Polypharmacy. Psychiatric Clinics of North America 35:3, pages 661-681.
Crossref
Crossref
Juan A. Gallego, John Bonetti, Jianping Zhang, John M. Kane & Christoph U. Correll. (2012) Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research 138:1, pages 18-28.
Crossref
Crossref